Aytu Biopharma (AYTU) investor relations material

Business transformation and strategic focus

• Transitioned to a CNS-focused commercial pharma model, generating over $60 million in annual revenue, primarily from ADHD and pediatric medications.

• Shifted commercial infrastructure to focus on psychiatry, leveraging relationships with psychiatric practices nationwide.

• Achieved consistent EBITDA positivity and near cash flow breakeven, enabling renewed business development efforts.

• In-licensed EXXUA, a novel antidepressant, to capitalize on existing infrastructure and address future growth.

EXXUA product differentiation and market opportunity

• EXXUA targets Major Depressive Disorder, a $22 billion U.S. market with 350 million annual prescriptions.

• Unlike SSRIs, EXXUA selectively modulates the 5-HT1A receptor, avoiding common side effects like weight gain and sexual dysfunction.

• Physicians and patients cite sexual side effects and weight gain as top reasons for switching or discontinuing antidepressants.

• Early patient anecdotes and physician feedback highlight significant improvements and strong adoption for treatment-resistant cases.

Market access, reimbursement, and RxConnect program

• EXXUA is typically prescribed after patients have failed two or more generic antidepressants, aligning with payer requirements.

• The proprietary RxConnect program partners with 1,000 pharmacies, capping copays at $50 and ensuring predictable pricing.

• RxConnect streamlines prior authorizations, increases patient and physician satisfaction, and drives high prescription stickiness.

• The program accounts for about 85% of dispensed prescriptions in the legacy business, supporting resilience against generic competition.